Dr. Reddy's Laboratories Limited filings document its U.S. reporting as a foreign private issuer with American depositary receipts listed on the New York Stock Exchange. Recent Form 6-K reports furnish exchange intimations and exhibits submitted to Indian exchanges and the NYSE, including board-meeting notices and other current-report disclosures.
The filing record centers on Rule 13a-16 and 15d-16 submissions, Form 20-F reporting status, governance communications, and public-company notices tied to Dr. Reddy's pharmaceutical operations and securities across India and the United States.
DR REDDYS LABORATORIES LTD filed an initial insider ownership report for Israeli Erez, who is listed as the company’s CHIEF EXECUTIVE OFFICER. This Form 3 shows no reported purchases, sales, or other transactions in the company’s securities and provides only role and status information.
Dr. Reddy's Laboratories Ltd officer Venkatesh Krishna, Global Head - IPDO, has filed an initial Form 3 as a reporting person. The filing in this excerpt lists no equity transactions or derivative positions, and serves mainly to establish his status as an insider subject to SEC reporting rules.
DR REDDYS LABORATORIES LTD executive Sushrut Kulkarni, Global Head - IPDO, filed an initial ownership report showing beneficial ownership of 70 Equity Shares of the company. These shares are reported as held under direct ownership, with no buy or sell transaction disclosed in this filing.
DR REDDYS LABORATORIES LTD reported the initial holdings of Chief Information Officer Bhethanabottla Srinivasa Phanimitra on a Form 3. The filing shows direct ownership of 8,712 Equity Shares after the reported entry. This is a disclosure of existing beneficial ownership rather than a new stock purchase or sale.
DR REDDYS LABORATORIES LTD Chief Financial Officer Mannam Venkata Narasimham filed an initial ownership report showing his stake in the company. The Form 3 lists direct ownership of 61,245 Equity Shares, providing a baseline of his holdings as an executive but does not report any recent share purchases or sales.
DR REDDYS LABORATORIES LTD executive Deepak Sapra has filed an initial Form 3 reporting his equity holdings. As CEO - API and Services, he reports beneficial ownership of 75,624 equity shares held directly. This filing lists his position as of the reporting date and does not show any recent buy or sell transaction.
DR REDDYS LABORATORIES LTD director Alpna Seth filed an initial Form 3, which identifies her as a reporting person for the company. The filing shows no reported transactions or derivative positions and serves as a baseline disclosure of her status under insider reporting rules.
DR REDDYS LABORATORIES LTD director Shikha Sanjaya Sharma has filed an initial Form 3 reporting beneficial ownership. The filing lists her status as a director of the company and shows no reported transactions, share purchases or sales, and no derivative positions at this time.
DR REDDYS LABORATORIES LTD director Sanjiv Soshil Mehta has filed an initial Form 3, which is a baseline statement of his beneficial ownership in the company’s securities. The filing does not report any stock purchases, sales, option exercises, or other transactions.
DR REDDYS LABORATORIES LTD director files initial ownership report
Penny Chan Wan, a director of DR REDDYS LABORATORIES LTD, filed an initial Form 3 reporting beneficial ownership in the company’s securities. The summary data in this filing shows no reported transactions or derivative positions and no separate holding entries at this time.